Lipid-Based Solutions to Increase Bioavailability Presented at Formulation & Drug Delivery Congress

Share Article

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Dr. Vincent Plassat, Scientific Affairs Manager, will present a workshop at the upcoming Formulation & Drug Delivery Congress, to be held at the Kensington Close Hotel, London, UK, on the 18th and 19th May, 2015.

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Dr. Vincent Plassat, Scientific Affairs Manager, will present a workshop at the upcoming Formulation & Drug Delivery Congress, to be held at the Kensington Close Hotel, London, UK, on the 18th and 19th May, 2015.

Dr. Plassat’s session, on Monday 18th at 9.30 a.m., is entitled “Accelerating the development of compounds with bioavailability limitations,” and will discuss the development of orally-delivered, lipid-based systems that can be used to improve the bioavailability of New Chemical Entities which offer therapeutic promise for patients, but exhibit limiting physico-chemical attributes for conventional, solid oral dose delivery.

Dr. Plassat joined Catalent in 2013, initially as a formulation scientist, drawing upon his experience in lipid-based softgel development for the oral delivery of macromolecules, before becoming Scientific Affairs Manager. Prior to joining Catalent, he worked at OTR3, a Paris-based startup company, developing targeted therapies.

Dr. Plassat is a pharmacist, and received a Ph.D. from the University of Paris Sud in Pharmaceutical Technologies.

For more information on the Formulation & Drug Delivery Congress, visit: http://www.formulation-congress.com and to arrange a meeting with Dr. Plassat, contact Richard Kerns at NEPR- richard(at)nepr(dot)eu.

Notes for Editors

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at 30 facilities across 5 continents, and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Halling

Richard Kerns
Northern Exposure PR
+44 7974 579202
Email >
Visit website